Physician profile
William L Eckstein
NPI 1619038171
$844.97
in general payments reported to CMS, 2019-2025
21 companies · $350 in 2025
The $350 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.25 · 2021: $68.76 · 2022: $96.75 · 2023: $81.11 · 2024: $230 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $158.98 | 2024-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.92 | 2021-2022 | |
| Tris Pharma INC | $66.08 | 2025 | Dyanavel Xr |
| Lilly USA, LLC | $55.33 | 2021-2023 | Mounjaro, Trulicity |
| Vanda Pharmaceuticals INC. | $45.34 | 2023-2024 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $44.45 | 2025 | Intracept |
| Supernus Pharmaceuticals, INC. | $41.15 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $38.21 | 2025 | Jornay Pm |
| Abiomed | $37.09 | 2024 | Impella |
| Ironshore Pharmaceuticals INC. | $30.49 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $29.28 | 2023 | Rexulti |
| Treace Medical Concepts, INC. | $20.57 | 2024 | |
| Verrica Pharmaceuticals INC. | $20.08 | 2025 | Ycanth |
| Janssen Pharmaceuticals, INC | $19.77 | 2024 | Invega Sustenna |
| Sanofi Pasteur INC. | $18.25 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $16.83 | 2024 | Valtoco |
| Merck Sharp & Dohme LLC | $16.34 | 2025 | M-M-R II, Gardasil 9, Proquad |
| Ultragenyx Pharmaceutical INC. | $16.22 | 2021 | |
| Glaxosmithkline, LLC. | $16.01 | 2024 | Rotarix, Bexsero |
| Teva Pharmaceuticals USA, INC. | $15.81 | 2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Eckstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.